News archives
These are the news articles that are older than a year. For the latest news, please visit the latest news page.
Board Appointment
21 July 2006
Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) (”Phytopharm”) announces the appointment with immediate effect of Dr Peter Robin Blower, former Director of New Neuroscience products at SmithKline Beecham as a non-executive Board Director of Phytopharm.
Appointment of Non Executive Director
5 June 2006
Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) (”Phytopharm”) announces the appointment with immediate effect of Mr A D (Sandy) Morrison, former CEO of Lipton Ltd (a Unilever subsidiary) as a Non-executive Board Director of Phytopharm.
Launch of Phytopica™
24 April 2006
Phytopharm responsible for manufacture and Schering-Plough Animal Health for marketing and distribution
Phytopharm successfully progresses to second stage of Joint Development Agreement for Hoodia gordonii extract with Unilever
10 April 2006
Second stage includes clinical safety studies
Phytopharm plc and Schering-Plough Animal Health enter into a Marketing and Distribution Agreement for Phytopica™
9 January 2006
PHYTOPHARM PLC AND SCHERING-PLOUGH ANIMAL HEALTH ENTER INTO A MARKETING AND DISTRIBUTION AGREEMENT FOR PHYTOPICA(TM)
Preliminary trial results expected December 2005
30 November 2005
Phytopharm plc (LSE:PYM; NASDAQBB: PHYOF; PHYOY) (’Phytopharm’) announces today that all subjects have now completed their participation in the phase II proof of principle clinical study of PYM50028 (CoganeTM). The compound is an orally active, synthetic, neuroprotective and neurotrophic product that is under development as a treatment for Alzheimer’s disease.
Board Change
30 November 2005
Phytopharm announced on 3rd November 2005 that Dr G W Chong is to step down as a director and Chief Financial Officer to pursue other interests and that this was expected to take effect at the latest on 3 May 2006. Dr Chong will now cease to be a director and Chief Financial Officer on 2nd December 2005.
Preliminary results of Phase II proof of principle study in Alzheimer's disease
28 November 2005
Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) (’Phytopharm’) announces today the preliminary results obtained from the Phase II proof of principle clinical study of PYM50028
Resignation of Joint Sponsor and Broker
23 June 2005
The Company announces that Canaccord Capital (Europe) Limited has resigned as the company’s joint sponsor and broker with immediate effect.
Interim results for the period to 28 February 2005
11 May 2005
Phytopharm plc has announced their Interim Results for the period to 28 February 2005.
